Radiotheragnostics in oncology; current status and future prespective

15^th International Conference on Pharmaceutical Education and Practice

August 10-11, 2023 | Webinar

Ghasemali Divband

Nuclear Medicine Center, Jam Hospital , Iran

Posters & Accepted Abstracts: J Biomed Pharm Sci

Abstract :

In recent years, radiotheragnostics refers to a rapidly evolving field of medicine in which disease is diagnosed followed by treatment of disease positive patients using tools for the therapy identical to those used for the diagnosis by imaging. Precision oncology leads the way in theragnostics innovation, where the approach has become possible with the identification of specific targets selectively expressed in cancer versus healthy tissue and graet advances in imaging technology. Now, radiotheragnostics using radiopharmaceuticals is becoming routine with favorable results in patients with prostate cancer and neuroendocrine tumors who express the receptors of PSMA and SSTR, respectively. We will discuss about current status and future prespective of this exciting field and it;s role in precision oncology.

Biography :

Ghasemali Divband has completed his education as Nuclear Medicine physician from Mashhad University of Medical Science. He is head of department of Nuclear Medicine and radionuclide therapy at Jam Hospital in Tehran-Iran. He has published more than 25 papers in reputed journals, manily in field of radionuclide therapy.